Tech Company Financing Transactions
Aerska Funding Round
On 2/9/2026, Aerska landed $39 million in Series A funding from EQT Growth and private investors.
Transaction Overview
Company Name
Announced On
2/9/2026
Transaction Type
Venture Equity
Amount
$39,000,000
Round
Series A
Investors
EQT Growth (Lead Investor) (Arno de Wilde)
Proceeds Purpose
The company intends to use the funds to advance its technology to improve delivery of RNAi interference (RNAi) therapeutics across the blood-brain barrier for treating neurological diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
251 Little Falls Drive
Wilmington, DE 19808
USA
Wilmington, DE 19808
USA
Phone
Undisclosed
Website
Email Address
Overview
Targeted delivery of RNA medicines to the brain. By silencing the genes that cause harm, we aim to preserve minds, protect memories, and enable our loved ones to live healthier, longer lives.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jack O'Meara
Chief Financial Officer
Andrew Cregan
Chief Scientific Officer
Duygu Yilmaz
Co-Founder
Stuart Milstein
VP - Bus. Development
David Coughlan
VP - Bus. Development
Dave Hardwicke
VP - Operations
Jess McDonald
VP - R & D
Michael Perkinton
Browse more venture capital transactions:
Prev: 2/9/2026: Dynasty Financial Partners venture capital transaction
Next: 2/9/2026: Topview venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs